Contact Us

High-Throughput Crystallography

  • SERVICES & SOLUTIONS
  • High-Throughput Crystallography


Advantages Methodology In Numbers Case Studies WHY CRELUX

High-Throughput Crystallography

High-throughput crystallography constitutes a scalable, often parallelized, automated X-ray crystallography workflow designed to rapidly generate and analyze large numbers of macromolecular structures. It enables systematic structural studies such as fragment or compound screening at highly competitive timelines without compromising on sensitivity.

At Crelux, a WuXi AppTec company, High-Throughput Crystallography enables our clients to go from Hit to Lead fast, gaining highly valuable and even unexpected insights into their target structures. For faster, more efficient and trusted results in early drug discovery.

Advantages

  • Direct identification of binding site and mode, including key interactions
  • Detection of unexpected binding sites and modes, including allosteric and cryptic pockets
  • High sensitivity, hit identification rates improved by more than 5%
  • Competitive timelines, 100s of crystals per week with 3 weeks from screen to structure
  • Established for diverse set of target classes, including CDKs, STATs and many more
  • Faster and more efficient Hit-to-Lead optimization

Methodology


Automated Liquid Handling
Automated liquid handling for precision and reproducibility
Automated Imaging Systems
Automated imaging systems for instant feedback on crystal growth
Acoustic Liquid Handling
Acoustic liquid handling for contact-free ligand transfer
Crystal Shifter
Crystal shifter for high-throughput crystal harvesting
Synchrotron Beamtime
Weekly beamtime with synchrotron partners for highest-resolution, fully automated data collection
IT Infrastructure
In-house IT infrastructure for diffraction data processing and structure determination

High-Throughput Crystallography in Numbers


Screening capacity/throughput: 100s crystals per week

Libraries: DSi Posed (860 fragments) and FragLites library (31 halogenated fragments)

7 beamline partnerships

10 successful screens delivered in 2026

Identified over 400 fragment bound structures

Up to 15% hit rate

Established for multiple crystal systems

Case Studies

Covalent Fragment Screening with BTK

Covalent Fragment Screening with BTK


Structure Based Identification of 40 Fragments with CDK2

Structure Based Identification of 40 Fragments with CDK2

WHY CRELUX

Based in Germany and part of the WuXi Biology network, Crelux has provided integrated early-stage drug discovery services for more than 20 years — from customized protein production and biophysical assays to hit validation and structure-guided optimization.

With deep expertise in structural biology and biophysics, we have developed and validated over 500 assays across a broad range of targets. Our multidisciplinary teams ensure fast turnaround, reproducible data, and smooth integration into downstream chemistry and biology workflows.

Crelux GmbH Your Partner in Early Stage Drug Discovery:
  • Proven success with >500 drug targets
  • Integrated workflows from target to lead
  • Trusted CRO partner for pharma and biotech worldwide for more than 20 years

Ready To Start your Project?

Your discovery projects deserve to receive the best possible support – talk to the experts!

Contact Us